PDD vs PAD to Treat Initially Diagnosed MM
The purpose of this study is to determine whether doxorubicin hydrochloride liposome is superior to doxorubicin when combined with bortizomib and dexamethasone for treating patient with initially diagnosed multiple myeloma.
Multiple Myeloma
DRUG: PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone|DRUG: PAD regimen: bortizomib, dexamethasone and doxorubicin
Response rate, sCR + CR + VGPR, 4 cycles (each cycle is 28 days) of chemotherapy
Overall remission rate, sCR + CR, 4 cycles (each cycle is 28 days) of chemotherapy|Progression-free survival, 3 year|Adverse Event, 3 year
The purpose of this study is to determine whether doxorubicin hydrochloride liposome is superior to doxorubicin when combined with bortizomib and dexamethasone for treating patient with initially diagnosed multiple myeloma.